Gilead Sciences (GILD)
NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-04
$151.00-0.15%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-04
Warn: Primary pillar under pressure — Total revenue near $30.2 billion: FY26 revenue guidance $30.15B vs $30.2B target; Q2 revenue $7.8B (+10.0% YoY).
Gilead grows product sales excluding Veklury to about $29.4 billion in 2026. Total revenue is expected near $30.2 billion this year. The Arcellx acquisition boosts its cancer drug portfolio. Profit margins and earnings remain stable with steady growth.
If product sales growth slows below 6.8% or revenue falls under $30 billion, earnings could weaken. The Arcellx deal might not add value soon. Competition or regulation could hurt sales and profits.
The price is about 4% above our fair value near $130. Analysts expect about 6% revenue growth. Our fair value is below the Street median, reflecting caution on growth and margins.
Breaks if: acquisition not completed or fails to add value by 2028
Finalize the acquisition of Arcellx to enhance oncology and inflammation portfolios.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on growth in product sales and strategic acquisitions. The current thesis is in a watch state, reflecting recent financial performance that remains strong but has shown signs of slipping.
The market appears to price GILD as relatively cheap compared to peers, with an expectations gap indicating that some negative factors may already be reflected in the valuation. The current valuation suggests that investors are cautious but not overly pessimistic about the company's future prospects.
Management has shown robust earnings quality and is on track with priorities like increasing product sales, though integration of new assets presents mixed results. Near-term risks are moderate, with a low probability of missing earnings expectations, but historical performance raises some caution.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a positive outlook. Gilead's growth in HIV and PrEP sales is notable. The company also announced a collaboration with Nucleai for AI in oncology. This partnership may enhance Gilead's clinical development programs. There are no new threats impacting the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: product sales excluding Veklury fall below $29.4B in FY26
Breaks if: total revenue falls below $30.0B in FY26
The thesis hinges on maintaining product sales growth, successful integration of acquired assets, and the overall performance of the healthcare sector. Key scenarios include the potential for a credibility hit if guidance is cut and the impact of broader economic conditions on the healthcare sector.
Over the next 1 to 3 years, GILD's performance will depend on its ability to execute on growth initiatives while navigating sector dynamics. Not investment advice.